Entecavir (ETV) monohydrate
Phase 2Small molecule
Johnson & JohnsonEntecavir (ETV) monohydrate is one of 72 small molecule programs targeting Chronic Hepatitis B Virus Infection. It is currently in Phase 2.
2
Indications
3
Total Trials
0
Active Trials
71
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
252 competitors in Hepatitis B
#DrugCompanyPhaseTrials
1Viread
GileadPhase 3
Hepatitis B Vaccine
SanofiPhase 3
YF-Vax
SanofiPhase 3
Virazole
CConrado Roberto Hoffmann Filho
Phase 3
Immunoglobulins
CSL BehringPhase 3
Recombinant Hepatitis B Vaccine
NovartisPhase 3
Hydronidone
BBeijing Continent Pharmaceutical Co, Ltd.
Phase 3
Polio Sabin.
GSKPhase 3
B/F/TAF
GileadPhase 3
Tritanrix/hiberix Vaccine
GSKPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Entecavir (ETV) monohydrate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company